Allouche Cyril 4
4 · Revance Therapeutics, Inc. · Filed Mar 19, 2019
Insider Transaction Report
Form 4
Allouche Cyril
Principal Financial Officer
Transactions
- Tax Payment
Common Stock
2019-03-15$15.45/sh−252$3,893→ 6,898 total - Sale
Common Stock
2019-03-18$15.48/sh−498$7,709→ 6,400 total
Footnotes (2)
- [F1]Represents the number of shares withheld by and surrendered to the issuer on March 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 2,250 shares. The RSA vests in three equal annual installments from March 15, 2018, subject to Mr. Allouche's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche.